Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Contact
Online Exclusives
Biosimilars Excellence Forum
Blogs
Expert Insights
Latest News
Mantle Cell Lymphoma Excellence Forum
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
Melanoma
Featured
Quiz
Quiz: Medicare Fee-for-Service Pricing Impact on Skin Cancer Procedures
True or False: Medicare fee-for-service pricing incentivizes use of Mohs micrographic surgery over other skin cancer procedures.
News
Medicare FFS Pricing Incentivizes Use of Mohs Micrographic Surgery Over Other Skin Cancer Procedures
Study results show Medicare payment rates for Mohs micrographic surgery more than double those of other procedures for…
News
Real-World Effectiveness of ICIs for Older Patients With Advanced Melanoma
Immune checkpoint inhibitor therapy deliver in a real-world setting significantly improves survival in patients aged 65…
News
Predictive Value of Circulating Tumor DNA in Melanoma Patients After First-Line Treatment With ICIs
Clinical outcomes of melanoma patients who may benefit from combination immunotherapy can be predicted with circulating…
News
Adjuvant Pembrolizumab Improves RFS in High-Risk Melanoma
Adjuvant pembrolizumab was found to provide a “sustained and clinically meaningful” improvement in RFS at a median…
News
Medicare FFS Pricing Incentivizes Use of Mohs Micrographic Surgery Over Other Skin Cancer Procedures
Real-World Effectiveness of ICIs for Older Patients With Advanced Melanoma
Predictive Value of Circulating Tumor DNA in Melanoma Patients After First-Line Treatment With ICIs
Adjuvant Pembrolizumab Improves RFS in High-Risk Melanoma
Guideline Updates
ASCO Updates Systemic Therapy Guideline for Melanoma
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top